New depression drug candidate passes first safety check in healthy volunteers
NCT ID NCT04981561
First seen Mar 25, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early-stage study tested the safety and tolerability of single doses of an experimental drug called AGN-241751 (zelquistinel) in 68 healthy volunteers. The goal was to see how the body handles the drug and if it causes any side effects, not to treat depression. The study is complete and helps pave the way for future research in people with major depressive disorder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.